Cargando…
Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis
BACKGROUND AND OBJECTIVE: PCOS is a common metabolic disorder in women of reproductive age, which pathogenesis is very complex. The role of ferroptosis in PCOS is a novel finding, and the mechanistic studies are not clear. Metformin is a commonly used drug of PCOS but few studies on whether metformi...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900736/ https://www.ncbi.nlm.nih.gov/pubmed/36755918 http://dx.doi.org/10.3389/fendo.2023.1070264 |
_version_ | 1784882910630772736 |
---|---|
author | Peng, Qingjie Chen, Xiaojiang Liang, Xiaoxia Ouyang, Jiahui Wang, Qiangqiang Ren, Shuai Xie, Haibo Wang, Chunhong Sun, Yaqun Wu, Xin Liu, Hetao Hei, Changchun Sun, Miao Chang, Qing Liu, Xinrui Li, Guangyong He, Rui |
author_facet | Peng, Qingjie Chen, Xiaojiang Liang, Xiaoxia Ouyang, Jiahui Wang, Qiangqiang Ren, Shuai Xie, Haibo Wang, Chunhong Sun, Yaqun Wu, Xin Liu, Hetao Hei, Changchun Sun, Miao Chang, Qing Liu, Xinrui Li, Guangyong He, Rui |
author_sort | Peng, Qingjie |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: PCOS is a common metabolic disorder in women of reproductive age, which pathogenesis is very complex. The role of ferroptosis in PCOS is a novel finding, and the mechanistic studies are not clear. Metformin is a commonly used drug of PCOS but few studies on whether metformin can improve the follicle development and ovarian function in PCOS. We aims to use PCOS mouse model to study the effect of metformin on PCOS based on the ovarian function and explored the regulation of metformin in PCOS mice by intervening in ferroptosis pathway. MATERIALS AND METHODS: C57 BL/6J female mice aged 4-5 weeks were purchased and gavaged with letrozole (1 mg/kg/day) combined with high-fat diet for 21days to establish PCOS model, and control group was set up. After modeling, the mice were divided into PCOS model group and metformin treatment group (Met) (n=6).The Met group were gavaged metformin (200 mg/kg/day) for 28 days. The body weight, estrous cycle, glucose tolerance test (OGTT)and insulin resistance test (ITT) were monitored. Then, The mice were euthanized to collect serum and ovaries. Elisa was used to detect changes in related serum hormones (E2, LH, FSH, TP). Ovaries used for molecular biology experiments to detect changes in GPX4, SIRT3, AMPK/p-AMPK, and mTOR/p-mTOR by Western blot and qPCR. RESULTS: Compared with the model group mice, body weight was significantly reduced, and their estrous cycle was restored in Met group. The results of OGTT and ITT showed an improvment of glucose tolerance and insulin resistance. Morphological results showed that after metformin treatment, polycystic lesions in ovaries were reduced, the ovarian function was restored, and the expressions of SIRT3 and GPX4 were elevated. WB results demonstrated that the expressions of p-mTOR and p-AMPK in ovaries were significantly reduced in Model group, but reversed in MET group. CONCLUSION: Our study confirmed metformin could not only improve body weight and metabolism disorders, but also improve ovarian dysfunction in PCOS mice.In addition, we explored metformin could regulate ferroptosis to improve PCOS via the SIRT3/AMPK/mTOR pathway. Our study complements the mechanisms by which metformin improves PCOS. |
format | Online Article Text |
id | pubmed-9900736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99007362023-02-07 Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis Peng, Qingjie Chen, Xiaojiang Liang, Xiaoxia Ouyang, Jiahui Wang, Qiangqiang Ren, Shuai Xie, Haibo Wang, Chunhong Sun, Yaqun Wu, Xin Liu, Hetao Hei, Changchun Sun, Miao Chang, Qing Liu, Xinrui Li, Guangyong He, Rui Front Endocrinol (Lausanne) Endocrinology BACKGROUND AND OBJECTIVE: PCOS is a common metabolic disorder in women of reproductive age, which pathogenesis is very complex. The role of ferroptosis in PCOS is a novel finding, and the mechanistic studies are not clear. Metformin is a commonly used drug of PCOS but few studies on whether metformin can improve the follicle development and ovarian function in PCOS. We aims to use PCOS mouse model to study the effect of metformin on PCOS based on the ovarian function and explored the regulation of metformin in PCOS mice by intervening in ferroptosis pathway. MATERIALS AND METHODS: C57 BL/6J female mice aged 4-5 weeks were purchased and gavaged with letrozole (1 mg/kg/day) combined with high-fat diet for 21days to establish PCOS model, and control group was set up. After modeling, the mice were divided into PCOS model group and metformin treatment group (Met) (n=6).The Met group were gavaged metformin (200 mg/kg/day) for 28 days. The body weight, estrous cycle, glucose tolerance test (OGTT)and insulin resistance test (ITT) were monitored. Then, The mice were euthanized to collect serum and ovaries. Elisa was used to detect changes in related serum hormones (E2, LH, FSH, TP). Ovaries used for molecular biology experiments to detect changes in GPX4, SIRT3, AMPK/p-AMPK, and mTOR/p-mTOR by Western blot and qPCR. RESULTS: Compared with the model group mice, body weight was significantly reduced, and their estrous cycle was restored in Met group. The results of OGTT and ITT showed an improvment of glucose tolerance and insulin resistance. Morphological results showed that after metformin treatment, polycystic lesions in ovaries were reduced, the ovarian function was restored, and the expressions of SIRT3 and GPX4 were elevated. WB results demonstrated that the expressions of p-mTOR and p-AMPK in ovaries were significantly reduced in Model group, but reversed in MET group. CONCLUSION: Our study confirmed metformin could not only improve body weight and metabolism disorders, but also improve ovarian dysfunction in PCOS mice.In addition, we explored metformin could regulate ferroptosis to improve PCOS via the SIRT3/AMPK/mTOR pathway. Our study complements the mechanisms by which metformin improves PCOS. Frontiers Media S.A. 2023-01-23 /pmc/articles/PMC9900736/ /pubmed/36755918 http://dx.doi.org/10.3389/fendo.2023.1070264 Text en Copyright © 2023 Peng, Chen, Liang, Ouyang, Wang, Ren, Xie, Wang, Sun, Wu, Liu, Hei, Sun, Chang, Liu, Li and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Peng, Qingjie Chen, Xiaojiang Liang, Xiaoxia Ouyang, Jiahui Wang, Qiangqiang Ren, Shuai Xie, Haibo Wang, Chunhong Sun, Yaqun Wu, Xin Liu, Hetao Hei, Changchun Sun, Miao Chang, Qing Liu, Xinrui Li, Guangyong He, Rui Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis |
title | Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis |
title_full | Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis |
title_fullStr | Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis |
title_full_unstemmed | Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis |
title_short | Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis |
title_sort | metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900736/ https://www.ncbi.nlm.nih.gov/pubmed/36755918 http://dx.doi.org/10.3389/fendo.2023.1070264 |
work_keys_str_mv | AT pengqingjie metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT chenxiaojiang metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT liangxiaoxia metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT ouyangjiahui metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT wangqiangqiang metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT renshuai metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT xiehaibo metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT wangchunhong metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT sunyaqun metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT wuxin metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT liuhetao metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT heichangchun metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT sunmiao metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT changqing metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT liuxinrui metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT liguangyong metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis AT herui metforminimprovespolycysticovarysyndromeinmicebyinhibitingovarianferroptosis |